News and Announcements
Amogen Pioneer Newly Onboard with Actinogen Medical
- Published November 16, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Dr George Morstyn is joining Actinogen Medical as a non-executive director as of December 1, 2017.
- He brings extensive drug development experience to the role, with many new products receiving marketing approval.
- Dr Morstyn will work with Actinogen’s high calibre team to guide and optimise the development of XanamemTM.
As announced November 2, 2017, Actinogen Medical (ASX: ACW) proudly welcomes Dr George Morstyn, as a non-executive director on the board, beginning December 1, 2017. Dr Morstyn, a pioneer drug developer and former Amgen Inc. Executive, usher extensive drug development studies to the role with massive new products receiving approval of the market and launching products during his tenureship at Amgen.
Having worked in the 1980’s with the legendary Professor Don Metcalf “Order of Australia and Companion of the Order, regarded as the father of modern haematology”, at the Walter and Eliza Hall Institute. Dr Morstyn actively assisted establishing and pioneering the clinical development of the haemopoietic colony stimulating factors, the present champion in the standard treatment of patients suffering from cancer after chemotherapy. He worked as esteemed Senior Vice-President of Development and Chief Medical Officer at US biotech tower, Amgen (NASDAQ: AMGM, market capitalisation: US$128 billion), upon joining Amgen in its early formative years in 1991, when the company was a blossoming biotech. At Amgen, he was the key person for the development of medications, treatments across all therapeutic areas, including neuroscience as well.
Dr Morstyn will join with Actinogen’s highly renowned team to lead and optimise the development of XanamemTM for Alzheimer’s disease and various neurodegenerative conditions. Under his strong leadership in the medical arena, he dominated the marketing approval of many new products and subsequent successful commercial launches.
About Actinogen Medical Ltd (ASX: ACW)
Actinogen Medical Limited (ASX:ACW) is an Australian, publicly-listed early clinical-stage biotechnology company focused on the treatment of cognitive impairment and Alzheimer’s disease.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
